Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

OX40 Ligand Mouse anti-Human, Brilliant Violet 421, Clone: ik-1, BD

Mouse Monoclonal Antibody

Manufacturer:  BD Biosciences 563766

Catalog No. BDB563766

Add to cart



The ik-1 monoclonal antibody specifically binds to OX40 Ligand (OX40L) which is also known as CD252 and CD134 Ligand. OX40L is encoded by TNFSF4 (Tumor necrosis factor (ligand) superfamily, member 4). OX40L a 34 kDa type II transmembrane glycoprotein that is expressed by dendritic cells, B cells, human umbilical vein endothelial cells (HUVEC) and other types of vascular endothelial cells. OX40L serves as a costimulatory ligand by binding to and signaling through OX40 (CD134) which is expressed on activated T cells. It also mediates adhesion of activated T cells or OX40-positive transformed cells to vascular endothelial cells. Monocyte-derived dendritic cells (MoDC) express OX40 Ligand after stimulation through CD40. Ligation of OX40 Ligand expressed by activated MoDC can significantly increase their cytokine production.



OX40 Ligand
CD252; OX40 Ligand; CD134 Ligand; CD134L; TNFSF4; GP34; TXGP1
Affinity Purified
Human OX40 Ligand Transfected Cell Line
50 Tests
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Flow Cytometry
Brilliant Violet 421
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
IgG1, κ
Provide Content Correction

We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit